Abacavir sulfate tablets

Produkt Beschreibung

Abacavir sulfate (Ziagen®) is a synthetic carbocyclic analogue of the endogenous nucleoside deoxyguanosine. As a foundational component of dual- and triple-agent antiretroviral therapy (ART)—often co-formulated in fixed-dose combinations such as abacavir/lamivudine or abacavir/dolutegravir/lamivudine—abacavir suppresses viral replication, elevates $\text{CD4}^+$ T-cell counts, and mitigates the progression of HIV-associated clinical immunodeficiency.

Clinical Profile & Pharmaceutical Formulations

• Active Pharmaceutical Ingredient: Abacavir sulfate (chemical name: $(1S,4R)\text{-4-[2-amino-6-(cyclopropylamino)-9}H\text{-purin-9-yl]cyclopent-2-en-1-yl}\text{methanol sulfate}$).

• Dosage Forms & Strengths:

  • Film-Coated Tablets: 300 mg abacavir (equivalent to 351 mg abacavir sulfate), typically scored, biconvex, and debossed with manufacturer identifiers.

  • Oral Solution: 20 mg/mL strawberry-banana flavored aqueous solution for pediatric or liquid-dependent regimens.

  • Fixed-Dose Combinations: Frequently formulated with lamivudine (600 mg/300 mg) or lamivudine and dolutegravir (600 mg/300 mg/50 mg).

Pharmacodynamics & Mechanism of Action

• Intracellular Phosphorylation: Abacavir is a prodrug that requires a unique three-step intracellular metabolic cascade catalyzed by cellular enzymes:

  1. Phosphorylation by adenosine phosphotransferase to abacavir monophosphate.

  2. Deamination by cytosolic enzymes to carbovir monophosphate ($\text{CBV-MP}$).

  3. Sequential phosphorylation by cellular kinases to the active moiety: carbovir 5′-triphosphate ($\text{CBV-TP}$).

• Reverse Transcriptase Inhibition & Chain Termination: $\text{CBV-TP}$ structurally mimics natural deoxyguanosine triphosphate ($\text{dGTP}$) and acts as a competitive substrate inhibitor against the HIV-1 reverse transcriptase enzyme.

• Chain Termination: Once incorporated into nascent viral cDNA strands, the lack of a 3′-hydroxyl ($3’\text{-OH}$) group prevents the formation of standard $3’\text{-to-}5’$ phosphodiester bonds required to attach subsequent nucleotides, resulting in irreversible premature viral DNA chain termination.

• Cellular DNA Polymerase Selectivity: Exhibits low inhibitory affinity for host human nuclear DNA polymerases $\alpha$, $\beta$, Und $\gamma$, resulting in significantly lower mitochondrial toxicity compared to earlier-generation didactic NRTIs (such as zidovudine or didanosine).

Pharmacokinetics & Biotransformation

• Absorption & Bioavailability: Rapidly and extensively absorbed following oral administration, demonstrating an absolute bioavailability of approximately 83% to 86%. Food does not significantly alter systemic exposure (AUC).

• Distribution: Lipophilic properties facilitate penetration across the blood-brain barrier, achieving cerebrospinal fluid (CSF) concentrations approximately 18% to 36% of concurrent plasma concentrations. Low plasma protein binding (~50%).

• Non-CYP Hepatic Clearance: Extensively metabolized hepatically without significant involvement of the cytochrome P450 enzyme system, avoiding typical CYP-mediated drug-drug interactions. Clearance occurs via two primary pathways:

  • Alcohol dehydrogenase ($\text{ADH}$), converting abacavir to the 5′-carboxylic acid derivative (~30%).

  • UDP-glucuronosyltransferase ($\text{UGT}$), forming the 5′-glucuronide conjugate (~36%).

• Elimination & Kinetics: Displays a short terminal plasma elimination half-life of 1.5 to 2.0 hours. However, the intracellular active metabolite ($\text{CBV-TP}$) exhibits an extended half-life exceeding 20 hours, supporting once-daily clinical dosing schedules. Renal excretion of unchanged abacavir accounts for less than 2% of the dose.

Critical Pharmacogenomic Warning: HLA-B*5701 & Hypersensitivity

• Mandatory Pre-Treatment Screening: Clinical guidelines mandate that all patients undergo pharmacogenomic screening for the human leukocyte antigen allele $\text{HLA-B*5701}$ prior to initiating abacavir.

• Abacavir Hypersensitivity Reaction (AHR): Carriage of the $\text{HLA-B*5701}$ allele is directly linked to an immune-mediated multi-organ hypersensitivity reaction. Abacavir binds non-covalently within the antigen-binding cleft of the $\text{HLA-B*5701}$ molecule, altering its peptide presentation specificity and triggering widespread activation of self-reactive $\text{CD8}^+$ T-cells.

• Clinical Presentation: Symptoms typically manifest within the first six weeks of therapy and involve at least two of the following organ systems:

  • Systemic: High fever, extreme fatigue, malaise.

  • Cutaneous: Maculopapular, generalized, or confluent rash.

  • Gastrointestinal: Severe nausea, vomiting, diarrhea, abdominal pain.

  • Respiratory: Dyspnea, cough, pharyngitis.

• Absolute Rechallenge Contraindication: If an AHR is suspected or diagnosed, abacavir must be permanently discontinued immediately. Rechallenging a patient following an AHR can cause rapid hemodynamic collapse, severe multi-organ failure, and death within hours.

Important Safety Information & Boxed Warnings

• Fatal Hypersensitivity Reactions: Outlined in a dedicated Boxed Warning. Patients who test positive for $\text{HLA-B*5701}$ must not be prescribed abacavir-containing regimens.

• Lactic Acidosis & Severe Hepatomegaly with Steatosis: Class warning applicable to nucleoside analogues, typically secondary to rare mitochondrial toxicity. Manifests with elevated serum lactate, tachypnea, nausea, and acute hepatic failure.

• Ethanol Interaction: Co-administration with ethanol competitively inhibits alcohol dehydrogenase ($\text{ADH}$), reducing abacavir clearance and increasing abacavir AUC by approximately 41%.

• Cardiovascular Considerations: Large observational cohort studies (such as the D:A:D study) have reported an association between current/recent abacavir use and an elevated risk of myocardial infarction. Caution is warranted in patients with substantial underlying cardiovascular risk factors